Abstract
Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abrahamson M, Barrett AJ, Salvesen G, Grubb A . 1986 J. Biol. Chem. 261: 11282–11289
Abrahamson M, Grubb A, Glafsson I, Lundwall A . 1987 FEBS Lett. 216: 229–233
Barrett AJ . 1987 Trends Biochem. Sci. 12: 193–196
Bobek LA, Levine MJ . 1992 Crit. Rev. Oral Biol. Med. 3: 307–332
Calkins CC, Sameni M, Koblinski J, Sloane BF, Moin K . 1998 J. Histochem. Cytochem. 46: 745–751
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159
Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D, Sordat B . 1992 Int. J. Cancer 52: 645–652
Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J, Mach L . 1999 Int. J. Cancer 83: 526–531
Cox JL, Sexton PS, Green TJ, Darmani NA . 1999 Melanoma Res. 9: 369–374
Foekens JA, Kos J, Peters HA, Krasoveck M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG . 1998 J. Clin. Oncol. 16: 1013–1021
Gaumann A, Hansen T, Kohler HH, Kommoss F, Mann W, Maurer J, Kirkpatrick CJ, Kriegsmann J . 2001 Pathol. Res. Pract. 197: 257–262
Hawley-Nelson P, Roop DR, Cheng CK, Krieg TM, Yuspa SH . 1988 Mol. Carcinol. 1: 202–211
Heidtmann HH, Hofmann M, Jacob E, Erbil C, Havemann K, Schwartz-Albiez R . 1989 Cancer Res. 49: 6960–6965
Heidtmann HH, Havemann K, Schwartz-Albiez R . 1992 Br. J. Cancer 65: 154–156
Hirai K, Yokoyama M, Asano G, Tanaka S . 1999 Hum. Pathol. 30: 680–686
Huh CT, Hakansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, Abrahamson M, Karlsson S . 1999 Mol. Pathol. 52: 332–340
Keppler D, Waridel P, Abrahamson M, Bachmann D, Berdoz J, Sordat B . 1994 Biochim. Biophys. Acta 1226: 117–125
Konduri SD, Rao CN, Chandrasekar N, Tasiou A, Mohanam S, Kim Y, Lakka SS, Dinh D, Olivero WC, Gujrati M, Foster DC, Kisiel W, Rao JS . 2001 Oncogene 20: 6938–6945
Kos J, Werle B, Lah T, Brunner N . 2000 Int. J. Biol. Markers 15: 84–89
Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I . 1997 Clin. Cancer Res. 3: 1815–1822
Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, Brunner N . 1998 Clin. Cancer Res. 4: 1511–1516
Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N . 2000 Clin. Cancer Res. 6: 505–511
Krepela E, Prochazka J, Karova B, Cermak J, Roubkova H . 1998 Neoplasma 45: 318–331
Laemmli NK . 1970 Nature 227: 680–685
Lah TT, Kokalj-Kunovar M, Kastelic L, Babnik J, Stolfa A, Rainer S, Turk V . 1992 Cancer Lett. 61: 243–253
Lah TT, Cercek M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskai I . 2000 Clin. Cancer Res. 6: 578–584
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S . 1980 Nature 284: 67–68
Liotta LA, Steeg PS, Stetler-Stevenson WG . 1991 Cell 64: 327–336
Mangge H, Liebmann P, Tanil H, Herrmann J, Wagner C, Gallistl S, Schauenstein K, Erwa W . 2000 Clin. Chim. Acta. 300: 195–202
Merz GS, Benedikz E, Schwenk V, Johansen TE, Vogel LK, Rushbrook JI, Wisniewski HM . 1997 J. Cell Physiol. 173: 423–432
Mignatti P, Rifkin DB . 1993 Physiol. Rev. 73: 161–195
Mort JS, Recklies AD, Poole AR . 1980 Biochem. Biophys Acta. 614: 134–143
Murnane MJ, Sheahan K, Ozdemirli M, Shuja S . 1991 Cancer Res. 51: 1137–1142
Pavlova A, Krupa JC, Mort JS, Abrahamson M, Bjork I . 2000 FEBS Lett. 487: 156–160
Pederson PH, Marienhagen K, Mork S, Bjerkvig R . 1993 Cancer Res. 53: 5158–5165
Qian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfater A . 1989 Cancer Res. 49: 4870–4875
Randers E, Erlandsen EJ . 1999 Clin. Chem. Lab. Med. 37: 389–395
Schmitt M, Janicke H, Graeff H . 1992 Fibrinolysis 6: 3–26
Sexton PS, Cox JL . 1997 Melanoma Res. 7: 97–101
Sheahan K, Shuja S, Murnane MJ . 1989 Cancer Res. 49: 3809–3814
Sloane BF . 1990 Semin. Cancer Biol. 1: 137–152
Sloane BF, Moin K, Lah TT . 1994 Aspects of the Biochemistry and Molecular Biology of Tumors Vol 2: Pretlow TG and Pretlow TH (eds) New York: Academic Press pp 411–466
Sloane BF, Moin K, Krepela E, Rozhin J . 1990 Cancer Metastasis Rev. 9: 333–352
Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE . 2000 Clin. Chem. 46: 193–197
Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Kos J, Skrk J . 2000 Clin. Cancer Res. 6: 1052–1062
Strojnik T, Kos J, Zidanik B, Golouh R, Lah T . 1999 Clin. Cancer Res. 5: 559–567
Sukoh N, Abe S, Nakajima I, Ogura S, Isobe H, Inoue K, Kawakami Y . 1994 Virchows Arch. 424: 33–38
Terada T, Ohta T, Minato H, Nakanuma Y . 1995 Hum. Pathol. 26: 746–752
Towbin H, Staehelim T, Gordon J . 1979 Proc. Natl. Acad. Sci. USA 76: 4350–4354
Watanabe M, Higashi T, Watanabe A, Osawa T, Sato Y, Kimura Y, Tominaga S, Hashimoto N, Yoshida Y, Morimoto S . 1989 Biochem. Med. Metab. Biol. 42: 21–29
Werle B, Lotterle H, Schanzenbacher U, Lah TT, Kalman E, Kayser K, Bulzebruck H, Schirren J, Krasovec M, Kos J, Spiess E . 1999 Br. J. Cancer 81: 510–519
Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M, Asano G . 2001 Surg. Today 31: 385–389
Yoshimura K, Tsuchida T, Kawamoto K . 2000 Oncol. Rep. 7: 27–31
Acknowledgements
This work was supported in part by a National Institute for Health grant CA 76350 to Jasti S Rao.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Konduri, S., Yanamandra, N., Siddique, K. et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21, 8705–8712 (2002). https://doi.org/10.1038/sj.onc.1205949
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205949
Keywords
This article is cited by
-
pH-dependent and dynamic interactions of cystatin C with heparan sulfate
Communications Biology (2021)
-
Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth
Scientific Reports (2020)
-
TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA
Cell Death Discovery (2017)
-
Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk
Scientific Reports (2015)
-
Clinical significance of CD146 and latexin during different stages of thyroid cancer
Molecular and Cellular Biochemistry (2013)